Follicular Lymphoma Drug Profiles and Clinical Trials-Global Trends and Analysis Review, H2 2017

  • ID: 4449822
  • Report
  • 368 pages
  • VPA Research
1 of 3
Lymphoma is a cancer type where uncontrollable growth of lymphocytes (WBCs) initiating from lymph glands or lymphatic tissue or other parts of the lymphatic system, including bone marrow, tonsils, testicles, spleen and lymph nodes.

This excess growth of lymphocytes often accumulates in lymph nodes. Though this accumulation can occur in any body part, commonly affected parts are armpits, neck and groin and rarely in lungs or bones.

The non- inheritable and non- contageous disease is one of the common types of cancer but can be treated with patients’ life expectancy remaining quite large post- treatment.

Genomic alterations in lymphocytes cause damage to the lifecycle of these cells, boosting the cell division rate or affecting the death period. However, causes for such gene changes are yet to be determined.

Phases:
Phases of Lymphoma cancer
  • Single group of lymph nodes (above or below diaphragm)
  • Multiple group of lymph nodes are affected(above or below diaphragm)
  • Expands to both sides of diaphragm
  • Expands to bone marrow or other body parts
Types of Lymphoma Cancer

Though two types of Lymphoma are defined, it is often difficult to determine the exact sub- type of Lymphoma.

* Hodgkin Lymphoma
In Hodgkin Lymphoma, the cancer cells called Reed- Sternberg (RS) cells, have a characteristic appearance under microscope.
Further subtypes-

Nodular Sclerosis: Lymph nodes contain Reed- Sternberg cells mixed with normal white blood cells

Mixed Cellularity: Lymph nodes contain several Reed- Sternberg cells in addition to several other cell types

Lymphocyte- rich: Lymph nodes contain several normal- appearing lymphocytes and classic Reed- Sternberg cells

Lymphocyte- depleted: Lymph nodes contain large volume of Reed- Sternberg cells and few normal lymphocytes

Nodular lymphocyte- predominant Hodgkin lymphoma: Lymph nodes contain several abnormal B cells and Reed- Sternberg cells are rarely observed

* Non- Hodgkin Lymphoma
Unlike Hodgkin Lymphoma, the cancer cells called Reed- Sternberg cells are absent in this subtype of Lymphoma

High grade NHL

* B- cell NHL Lymphoma
Diffuse large B- cell (DLBCL): Abnormal growth of large B- Cells in different body parts

Intravascular B- Cell: Occurs due to explosion of lymphocytes within tiny vessels with no involvement of the organ parenchyma

Primary mediastinal large B- cell: Large neoplastic cells with B- cell derivation are observed

Burkitt: Most aggressive form, classified as endemic (African) type, sporadic type and HIV related

Primary central nervous system: DLBCL sub- type affecting the brain and or spinal cord

* T- cell NHL Lymphoma
Peripheral T- cell (PTCL NOS): Abnormal growth of T- cells which are not specified under any category

Anaplastic large cell: It can occur in the skin or in other organs throughout the body

Angioimmunoblastic T- cell: the body’s immune system does not recognize, and consequently destroys, its own cells and tissues

Enteropathy- associated: occurs in the intestines and is mostly associated with celiac disease

Nasal- type NK/T- cell: Natural killer cells often affecting the nasal area, trachea, gastrointestinal tract, or skin

Hepatosplenic T- cell: Abnormal growth of T- cells in liver or spleen

Lymphoblastic: The T- cells outgrow in number when a bone marrow cell develops alterations in its gene code

Low Grade NHL
Follicular: B- cells are affected; Enlargement of the lymph nodes in the neck, underarm, stomach, groin

Small lymphocytic: B- lymphocytes, with enlarged nodes affecting neck, armpit or groin

Lympho- plasmacytic: Enlarged cells make varying volumes of immunoglobin M protein in the blood, making it thick (condition referred to as Waldenstrom macroglobulinemi)

MALT Lymphoma (Gastric and Non- gastric): mucosa- associated lymphoid tissue (MALT) starts outside lymph nodes, usually in lymphatic tissue in the mucous membranes or tissues lining organs

Splenic marginal zone: The NHL sub- type affects spleen, bone marrow and blood

Nodal marginal zone: Mostly occurs in lymph nodes and rarely in spleen or bone marrow
Follicular Lymphoma clinical trials report provides comprehensive analysis and trends in global Follicular Lymphoma disease clinical trials. The research work analyzes the evolution of Follicular Lymphoma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Follicular Lymphoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Follicular Lymphoma clinical trials.

Major drugs under development in Follicular Lymphoma are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report
  • Number of Follicular Lymphoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Follicular Lymphoma
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Follicular Lymphoma clinical trials worldwide are listed
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
High grade NHL
Low Grade NHL
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010- 2017
2.2.3 Prominent Companies in Global Follicular Lymphoma Trials, 2010- 2017

3 Follicular Lymphoma Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Follicular Lymphoma
3.2 Follicular Lymphoma Product Snapshots
3.2.1 Follicular Lymphoma Drug Profiles

4 Global Follicular Lymphoma Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010- 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010- 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010- 2017
4.4 Subjects Recruited by Region, 2010- 2017
4.5 Clinical Trials by Year, 2010- 2017
4.6 Subjects Recruited by Year, 2010- 2017
4.7 Clinical Trials by Development Phase, 2010- 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010- 2017
4.9 Clinical Trials by Status, 2010- 2017
4.10 Subjects Recruited by Trial Status, 2010- 2017
4.11 Clinical Trials by Sponsor Type, 2010- 2017
4.12 Subjects Recruited by Sponsor Type, 2010- 2017
4.13 Clinical Trials by Economy Type, 2010- 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010- 2017

5 Africa Follicular Lymphoma Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Africa, 2010- 2017
5.1.1 Africa, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Africa, 2010- 2017
5.2.1 Africa, Total Enrolment by Country
5.3 Africa, Clinical Trials by Year, 2010- 2017
5.4 Africa, Clinical Trials by Development Phase, 2010- 2017
5.5 Africa, Clinical Trials by Trial Status, 2010- 2017
5.6 Africa, Clinical Trials by Sponsor Type, 2010- 2017

6 Europe Follicular Lymphoma Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in Europe, 2010- 2017
6.1.1 Europe, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in Europe, 2010- 2017
6.2.1 Europe, Total Enrolment by Country
6.3 Europe, Clinical Trials by Year, 2010- 2017
6.4 Europe, Clinical Trials by Development Phase, 2010- 2017
6.5 Europe, Clinical Trials by Trial Status, 2010- 2017
6.6 Europe, Clinical Trials by Sponsor Type, 2010- 2017

7 Western Pacific Follicular Lymphoma Clinical Trial Research Trends
7.1 Clinical Trials by Top Countries in Western Pacific, 2010- 2017
7.1.1 Western Pacific, Clinical Trials by Country
7.2 Subjects Recruited by Top Countries in Western Pacific, 2010- 2017
7.2.1 Western Pacific, Total Enrolment by Country
7.3 Western Pacific, Clinical Trials by Year, 2010- 2017
7.4 Western Pacific, Clinical Trials by Development Phase, 2010- 2017
7.5 Western Pacific, Clinical Trials by Trial Status, 2010- 2017
7.6 Western Pacific, Clinical Trials by Sponsor Type, 2010- 2017

8 Eastern Mediterranean Follicular Lymphoma Clinical Trial Research Trends
8.1 Clinical Trials by Top Countries in Eastern Mediterranean, 2010- 2017
8.1.1 Eastern Mediterranean, Clinical Trials by Country
8.2 Subjects Recruited by Top Countries in Eastern Mediterranean, 2010- 2017
8.2.1 Eastern Mediterranean, Total Enrolment by Country
8.3 Eastern Mediterranean, Clinical Trials by Year, 2010- 2017
8.4 Eastern Mediterranean, Clinical Trials by Development Phase, 2010- 2017
8.5 Eastern Mediterranean, Clinical Trials by Trial Status, 2010- 2017
8.6 Eastern Mediterranean, Clinical Trials by Sponsor Type, 2010- 2017

9 South East Asia Follicular Lymphoma Clinical Trial Research Trends
9.1 Clinical Trials by Top Countries in South East Asia, 2010- 2017
9.1.1 South East Asia, Clinical Trials by Country
9.2 Subjects Recruited by Top Countries in South East Asia, 2010- 2017
9.2.1 South East Asia, Total Enrolment by Country
9.3 South East Asia, Clinical Trials by Year, 2010- 2017
9.4 South East Asia, Clinical Trials by Development Phase, 2010- 2017
9.5 South East Asia, Clinical Trials by Trial Status, 2010- 2017
9.6 South East Asia, Clinical Trials by Sponsor Type, 2010- 2017

10 North America Follicular Lymphoma Clinical Trial Research Trends
10.1 Clinical Trials by Top Countries in North America, 2010- 2017
10.1.1 North America, Clinical Trials by Country
10.2 Subjects Recruited by Top Countries in North America, 2010- 2017
10.2.1 North America, Total Enrolment by Country
10.3 North America, Clinical Trials by Year, 2010- 2017
10.4 North America, Clinical Trials by Development Phase, 2010- 2017
10.5 North America, Clinical Trials by Trial Status, 2010- 2017
10.6 North America, Clinical Trials by Sponsor Type, 2010- 2017

11 South and Central America Follicular Lymphoma Clinical Trial Research Trends
11.1 Clinical Trials by Top Countries in South and Central America, 2010- 2017
11.1.1 South and Central America, Clinical Trials by Country
11.2 Subjects Recruited by Top Countries in South and Central America, 2010- 2017
11.2.1 South and Central America, Total Enrolment by Country
11.3 South and Central America, Clinical Trials by Year, 2010- 2017
11.4 South and Central America, Clinical Trials by Development Phase, 2010- 2017
11.5 South and Central America, Clinical Trials by Trial Status, 2010- 2017
11.6 South and Central America, Clinical Trials by Sponsor Type, 2010- 2017

12 Recent Clinical Trials- Snapshots
12.1 Follicular Lymphoma Trial Snapshots- 2017
12.2 Follicular Lymphoma Trial Snapshots- 2016
12.3 Follicular Lymphoma Trial Snapshots- 2015
12.4 Follicular Lymphoma Trial Snapshots- 2014
12.5 Follicular Lymphoma Trial Snapshots- 2013
12.6 Follicular Lymphoma Trial Snapshots- 2012
12.7 Follicular Lymphoma Trial Snapshots- 2011
12.8 Follicular Lymphoma Trial Snapshots- 2010

13 Appendix
13.1 About the Author
13.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Follicular Lymphoma- Average Enrolment by Country, 2010- 2017
Figure 2: Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 3: Follicular Lymphoma- Country wise Recruiting Sites, 2010- 2017
Figure 4: Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 5: Global Follicular Lymphoma Clinical Trials Participation Share by Region, 2010- 2017
Figure 6: Global Follicular Lymphoma Subjects Recruited by Region, 2010- 2017
Figure 7: Global Follicular Lymphoma Clinical Trials by Year, 2010- 2017
Figure 8: Global Follicular Lymphoma Subjects Recruited by Year, 2010- 2017
Figure 9: Global Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 10: Global Follicular Lymphoma- Subjects Recruited by Phase, 2010- 2017
Figure 11: Global Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 12: Global Follicular Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 13: Global Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 14: Global Follicular Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 15: Global Follicular Lymphoma- Clinical Trials by Type of Economy, 2010- 2017
Figure 16: Africa Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 17: Africa Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 18: Africa Follicular Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 19: Africa Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 20: Africa Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 21: Africa Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 22: Europe Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 23: Europe Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 24: Europe Follicular Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 25: Europe Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 26: Europe Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 27: Europe Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 28: Western Pacific Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 29: Western Pacific Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 30: Western Pacific Follicular Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 31: Western Pacific Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 32: Western Pacific Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 33: Western Pacific Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 34: Eastern Mediterranean Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 35: Eastern Mediterranean Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 36: Eastern Mediterranean Follicular Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 37: Eastern Mediterranean Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 38: Eastern Mediterranean Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 39: Eastern Mediterranean Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 40: South East Asia Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 41: South East Asia Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 42: South East Asia Follicular Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 43: South East Asia Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 44: South East Asia Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 45: South East Asia Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 46: North America Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 47: North America Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 48: North America Follicular Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 49: North America Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 50: North America Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 51: North America Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 52: South and Central America Follicular Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 53: South and Central America Follicular Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 54: South and Central America Follicular Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 55: South and Central America Follicular Lymphoma Trials by Phase, 2010- 2017
Figure 56: South and Central America Follicular Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 57: South and Central America Follicular Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017

1.2 List of Tables
Table 1: Follicular Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Follicular Lymphoma- Region wise Clinical Trials, 2010- 2017
Table 3: Follicular Lymphoma- Region wise Subjects Recruited, 2010- 2017
Table 4: Global Follicular Lymphoma- Clinical Trials and Subjects by Trial Type, 2010- 2017
Table 5: Follicular Lymphoma Trial Snapshots- 2017
Table 6: Follicular Lymphoma Trial Snapshots- 2017
Table 7: Follicular Lymphoma Trial Snapshots- 2017
Table 8: Follicular Lymphoma Trial Snapshots- 2017
Table 9: Follicular Lymphoma Trial Snapshots- 2017
Table 10: Follicular Lymphoma Trial Snapshots- 2017
Table 11: Follicular Lymphoma Trial Snapshots- 2017
Table 12: Follicular Lymphoma Trial Snapshots- 2017
Table 13: Follicular Lymphoma Trial Snapshots- 2017
Table 14: Follicular Lymphoma Trial Snapshots- 2017
Table 15: Follicular Lymphoma Trial Snapshots- 2017
Table 16: Follicular Lymphoma Trial Snapshots- 2017
Table 17: Follicular Lymphoma Trial Snapshots- 2017
Table 18: Follicular Lymphoma Trial Snapshots- 2017
Table 19: Follicular Lymphoma Trial Snapshots- 2017
Table 20: Follicular Lymphoma Trial Snapshots- 2017
Table 21: Follicular Lymphoma Trial Snapshots- 2017
Table 22: Follicular Lymphoma Trial Snapshots- 2017
Table 23: Follicular Lymphoma Trial Snapshots- 2017
Table 24: Follicular Lymphoma Trial Snapshots- 2017
Table 25: Follicular Lymphoma Trial Snapshots- 2017
Table 26: Follicular Lymphoma Trial Snapshots- 2017
Table 27: Follicular Lymphoma Trial Snapshots- 2017
Table 28: Follicular Lymphoma Trial Snapshots- 2017
Table 29: Follicular Lymphoma Trial Snapshots- 2017
Table 30: Follicular Lymphoma Trial Snapshots- 2017
Table 31: Follicular Lymphoma Trial Snapshots- 2017
Table 32: Follicular Lymphoma Trial Snapshots- 2017
Table 33: Follicular Lymphoma Trial Snapshots- 2017
Table 34: Follicular Lymphoma Trial Snapshots- 2017
Table 35: Follicular Lymphoma Trial Snapshots- 2017
Table 36: Follicular Lymphoma Trial Snapshots- 2017
Table 37: Follicular Lymphoma Trial Snapshots- 2017
Table 38: Follicular Lymphoma Trial Snapshots- 2017
Table 39: Follicular Lymphoma Trial Snapshots- 2017
Table 40: Follicular Lymphoma Trial Snapshots- 2017
Table 41: Follicular Lymphoma Trial Snapshots- 2017
Table 42: Follicular Lymphoma Trial Snapshots- 2017
Table 43: Follicular Lymphoma Trial Snapshots- 2017
Table 44: Follicular Lymphoma Trial Snapshots- 2017
Table 45: Follicular Lymphoma Trial Snapshots- 2017
Table 46: Follicular Lymphoma Trial Snapshots- 2017
Table 47: Follicular Lymphoma Trial Snapshots- 2017
Table 48: Follicular Lymphoma Trial Snapshots- 2017
Table 49: Follicular Lymphoma Trial Snapshots- 2017
Table 50: Follicular Lymphoma Trial Snapshots- 2017
Table 51: Follicular Lymphoma Trial Snapshots- 2017
Table 52: Follicular Lymphoma Trial Snapshots- 2017
Table 53: Follicular Lymphoma Trial Snapshots- 2017
Table 54: Follicular Lymphoma Trial Snapshots- 2017
Table 55: Follicular Lymphoma Trial Snapshots- 2017
Table 56: Follicular Lymphoma Trial Snapshots- 2017
Table 57: Follicular Lymphoma Trial Snapshots- 2017
Table 58: Follicular Lymphoma Trial Snapshots- 2017
Table 59: Follicular Lymphoma Trial Snapshots- 2017
Table 60: Follicular Lymphoma Trial Snapshots- 2017
Table 61: Follicular Lymphoma Trial Snapshots- 2017
Table 62: Follicular Lymphoma Trial Snapshots- 2017
Table 63: Follicular Lymphoma Trial Snapshots- 2016
Table 64: Follicular Lymphoma Trial Snapshots- 2016
Table 65: Follicular Lymphoma Trial Snapshots- 2016
Table 66: Follicular Lymphoma Trial Snapshots- 2016
Table 67: Follicular Lymphoma Trial Snapshots- 2016
Table 68: Follicular Lymphoma Trial Snapshots- 2016
Table 69: Follicular Lymphoma Trial Snapshots- 2016
Table 70: Follicular Lymphoma Trial Snapshots- 2016
Table 71: Follicular Lymphoma Trial Snapshots- 2016
Table 72: Follicular Lymphoma Trial Snapshots- 2016
Table 73: Follicular Lymphoma Trial Snapshots- 2016
Table 74: Follicular Lymphoma Trial Snapshots- 2016
Table 75: Follicular Lymphoma Trial Snapshots- 2016
Table 76: Follicular Lymphoma Trial Snapshots- 2016
Table 77: Follicular Lymphoma Trial Snapshots- 2016
Table 78: Follicular Lymphoma Trial Snapshots- 2016
Table 79: Follicular Lymphoma Trial Snapshots- 2016
Table 80: Follicular Lymphoma Trial Snapshots- 2016
Table 81: Follicular Lymphoma Trial Snapshots- 2016
Table 82: Follicular Lymphoma Trial Snapshots- 2016
Table 83: Follicular Lymphoma Trial Snapshots- 2016
Table 84: Follicular Lymphoma Trial Snapshots- 2016
Table 85: Follicular Lymphoma Trial Snapshots- 2016
Table 86: Follicular Lymphoma Trial Snapshots- 2016
Table 87: Follicular Lymphoma Trial Snapshots- 2016
Table 88: Follicular Lymphoma Trial Snapshots- 2016
Table 89: Follicular Lymphoma Trial Snapshots- 2016
Table 90: Follicular Lymphoma Trial Snapshots- 2016
Table 91: Follicular Lymphoma Trial Snapshots- 2016
Table 92: Follicular Lymphoma Trial Snapshots- 2016
Table 93: Follicular Lymphoma Trial Snapshots- 2016
Table 94: Follicular Lymphoma Trial Snapshots- 2016
Table 95: Follicular Lymphoma Trial Snapshots- 2016
Table 96: Follicular Lymphoma Trial Snapshots- 2016
Table 97: Follicular Lymphoma Trial Snapshots- 2016
Table 98: Follicular Lymphoma Trial Snapshots- 2016
Table 99: Follicular Lymphoma Trial Snapshots- 2016
Table 100: Follicular Lymphoma Trial Snapshots- 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll